GlaxoSmithKline plc today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash